ABSTRACT The seemingly unpredictable occurrence of paroxysmal supraventricular tachycardia has impeded understanding of its clinical course. We documented recurring tachycardia by telephone transmission of the electrocardiogram in 14 patients and measured the "tachycardia-free periods" between the start of therapy and the first recurrence of tachycardia and between successive recurrences. We showed that attacks of tachycardia were clinically independent by calculating the autocorrelation function for 12 to 14 consecutive tachycardia-free periods. We also found that the periods between attacks closely fit an exponential probability distribution, indicating that the occurrence of tachycardia in time was a type of random event called a Poisson process. Furthermore, occurrence of tachycardia was uniformly distributed throughout a dosing interval; there was no predilection for tachycardia to occur late in a dosing interval when plasma drug levels were presumed to be lowest. Measuring the tachycardia-free period is a simple and useful method for objectively studying paroxysmal supraventricular tachycardia and may be applied to the study of other paroxysmal arrhythmias. Circulation 70, No. 1, 1-6, 1984. PAROXYSMAL supraventricular tachycardia occurs sporadically in affected patients; attacks sometimes occur daily and at other times may be separated by weeks or months. This seemingly unpredictable behavior has made it difficult for clinicians to understand apparent changes in the clinical courses of their patients, who may be free of their arrhythmia for relatively long periods and then have two attacks close together for no apparent reason. In addition, the apparently capricious nature of this arrhythmia has been a substantial obstacle to measuring objectively the results of treatment in scientific studies. Follow-up in antiarrhythmic drug studies usually has been reported in subjective terms, has used nonquantitative variables, or has been totally ignored in favor of short-term observations.'-3
tachycardia. In this study we have used telephone transmission of the electrocardiogram to document recurrences in outpatients, and we have measured the time between episodes of tachycardia. 4 5 By examining the relationships among these successive time periods we found that the apparently chaotic nature of this arrhythmia actually was governed by common principles of probability and chance. These principles can be used to plan better clinical management of these patients and can be adapted to develop a highly reproducible measurement system for clinical trials.
Methods
Patients. The 14 subjects (10 men and four women; mean age 46 + 16 years) for this study were referred for treatment of a paroxysmal supraventricular tachycardia defined by the following electrocardiographic criteria: (1) ventricular rate greater than 120 beats/min, (2) QRS morphology that was normal, or functional right or left bundle branch block, (3) less than 0.02 sec variation in successive RR intervals, (4) no evidence of atrioventricular dissociation, and (5) episodic occurrence. The term "tachycardia" in the remainder of this manuscript describes this arrhythmia unless specified otherwise. Most tachycardias meeting this description in our hospital are atrioventricular reentrant tachycardias (with conduction in the antegrade direction over the atrioventricular node and conduction in the retrograde direction over an accessory pathway) or are caused by reentry within the atrioventricular node.6 None of the patients had any "trigger" activity by which he or she could predictably initiate tachycardia. NO 1 1984 Protocol. The methods used in this study were developed to address several questions about the behavior of this tachycardia. These questions included the following: Are attacks of tachycardia clinically independent or do they tend to We collected data for the present study from patients who were maintained on a particular medication regimen while several consecutive attacks of tachycardia were recorded. We then analyzed the data from these treatment periods to characterize the spontaneous occurrence of tachycardia in treated patients. For each treatment we calculated the "tachycardia-free periods" from the beginning of therapy to the first recurrence of tachycardia and then between successive attacks. We first examined the relationship between successive attacks of tachycardia in four patients who were followed up for 12, 12, 13, and 14 consecutive attacks. The follow-up time required to capture these data ranged from 58 days to 171 days; these four patients were specially selected because of their ability to cooperate over a long follow-up period and their willingness to endure the same medication regimen despite many attacks of tachycardia.
We first wanted to know whether the episodes of tachycardia were clinically independent or whether the occurrence of tachycardia was related to some previous attack. We assessed this by calculating the "autocorrelation function" for each patient.8
The autocorrelation function is a series of correlation coefficients that compare each tachycardia-free period with those preceding it. The first number in the series (lag 0) correlates each tachycardia-free period with itself, and it is always 1.0.
The second number (lag 1) correlates each period with the one immediately before it; the third number (lag 2) correlates each period with the second one before it, and so forth. If the successive attacks of tachycardia occurred independently, then the autocorrelation coefficient would be near 0.0 for all except the lag 0, which is what we expected to find.
After we had tested for independence in this way, we used the tachycardia-free periods to determine the probability model that described the occurrence of tachycardia. Many random events in biologic systems fit an exponential probability distribution9:
The properties of this distribution (described below and in the Discussion) seemed to agree with our impression of the clinical behavior of this tachycardia. We therefore fit the data from each patient to this distribution by calculating the parameter lambda.
We then tested how well our observed data fit the calculated exponential distribution by using the Kolmogorov-Smirnov method. 10
Random events with interevent times that fit an exponential probability distribution are often described as a "Poisson process. "9 If the occurrence of tachycardia were a Poisson process, then the probability of tachycardia happening on any given day would be independent of the time since the previous attack. That is, for any given patient, the probability of having tachycardia on a specified day was not influenced if the last attack was the day before, the week before, or the month before. As a supporting test for this phenomenon in all 14 patients followed up on 25 treatments, we used life-table methods to calculate the cumulative percentage of patients free of tachycardia during a 60 day follow-up period. l l We calculated these curves between the first dose of treatment and the first attack of tachycardia (dose-T1) and between TI and the second attack of tachycardia (TI-T2) (figure 1). We compared these life-table type curves for the intervals dose-Tl and TI-T2 and expected to find that the two curves were nearly identical.
Since some patients had tachycardia before steady-state plasma drug levels were achieved, we defined a new interval, "steady-state Tl. "12 Follow-up began on the first morning after steady-state plasma drug levels were achieved (sixth dose of medication), and the interval steady-state-Tl was measured from the start of follow-up to the next attack of tachycardia (figure 1). (Using the interval steady-state-Tl, we excluded episodes of tachycardia recorded before steady-state plasma drug levels were achieved.) We then calculated the cumulative percentage of patients free of tachycardia during 60 days of follow-up for steady-state-Tl and TI-T2.
Finally, we determined when tachycardia occurred with respect to time of day and to the elapsed time since previous dose of medication. We selected 19 treatment periods during which 13 patients were taking either 120 mg qid verapamil or 90 mg qid diltiazem. Five patients took only verapamil, two patients took only diltiazem, and six patients took verapamil first and later took diltiazem. We calculated the cumulative occurrence of tachycardia throughout the day and the cumulative occurrence of tachycardia for the 6 hr interval after a dose was calculated.
These studies were approved by the Medical Center Committee for Clinical Investigations.
Results
In the four subjects undergoing prolonged follow-up (12 to 14 consecutive attacks), the autocorrelation function showed that the consecutive tachycardia-free periods were uncorrelated. to the first recurrence of tachycardia. The interval steady-state-TI began on the first morning after steady-state plasma drug levels were reached and ended with the next attack of tachycardia. The interval TI-T2 was the interval between the first and second attacks of tachycardia.
the conclusion that successive attacks of tachycardia were independent events in a clinical sense. The tachycardia-free periods from these four patients were then fit to exponential probability distributions. The calculated parameters of the distribution were .129, .113, .076, and .296, respectively, for patients with 12, 12, 13, and 14 attacks recorded. Figure 2 , B, shows the observed data and the calculated curve for the same patient whose data are shown in figure 2 , A. The shaded area shows the 95% confidence interval for this curve; it appears fairly broad because the number of data points is relatively small. However, using the Kolmogorov-Smirnov method we tested how well the calculated curve fit the observed data for each patient, and there were no significant departures from the exponential distribution.
The cumulative percentage of subjects free of tachycardia during a 60 day follow-up period was calculated for a total of 25 treatments in all 14 patients (figure 3, A). Each step in the curve for dose-TI corresponds to a day when one or more patients had an attack of tachycardia. By the fifth day, half the subjects had already had tachycardia; by the twelfth day, three-fourths of the subjects had had tachycardia. All the subjects had had tachycardia by day 43.
The curve for TI-T2 is nearly identical to that for dose-TI. By the fifth day, half the subjects again had had tachycardia; by the twelfth day, three-fourths of them again had had tachycardia. All the subjects had tachycardia by day 59. When we allowed plasma drug levels to reach steady-state and measured steady-state-T1 instead of dose-T1, similar results were obtained ( figure 3, B) . The curves for steady-state-TI and TI-T2 were also nearly identical. This finding was not surprising, since relatively few patients actually had tachycardia before steady-state plasma drug levels were reached.
When we looked at the relationship between occurrence of tachycardia and the elapsed time since the preceding dose of antiarrhythmic drug, we found that 53% of the tachycardias were recorded in the first 3 hr after the dose and 47% were recorded in the last 3 hr ( figure 4, A) . The occurrence of tachycardia was uniformly distributed throughout the dosing interval; there was no predilection for occurrence late in the dosing interval when plasma drug levels were presumed to be lowest.
Interestingly, occurrences of tachycardia also were distributed uniformly throughout the waking hours between 9 A.M. and midnight ( figure 4, B) . No symptomatic tachycardia was recorded during the sleeping hours between midnight and 9 A.M.
Discussion
Results of these studies, obtained by telephone transmission of the electrocardiogram to document symptomatic occurrences of tachycardia, show that recurrences of this arrhythmia in a group of patients actually are quite predictable with standard probability techniques. To demonstrate that a specific probability model was applicable, we first showed that there was an absence of any correlation pattern between successive attacks of tachycardia ( figure 2, A) . The lack of any correlation can be interpreted as showing that the attacks of tachycardia were clinically independent. In addition, we found that the tachycardia-free periods measured between consecutive attacks closely fit an exponential probability distribution. occurring in a given time interval is proportional to the length of the interval. Thus, the longer a patient is followed, the more likely he is to have two closely spaced attacks of tachycardia at some point. These observations provide some insight into the management of patients with this arrhythmia. We should, for example, be cautious about blaming a changing disease pattern when a previously well-controlled patient has two closely spaced attacks. On probability grounds alone, these clusters will be seen in most patients if they are followed carefully for long enough. In the routine office management of patients, a minimum of three attacks should be recorded before a decision is made to abandon therapy, particularly a previously successful one. . . . . . . . . . . . . . . . . . . . . . . . . ,  . . . . . . . . . . . . . . . . . , . s ,  . . . . . . . . . . . . . . _ v  . . . . . . . . . That we found an exponential probability distribution of tachycardia-free periods indicated that this paroxysmal supraventricular tachycardia behaved like a Poisson process.9 Such systems are common in biology and medicine, and they have two characteristics that are very important for understanding this tachycardia. First, the probability of an event (such as tachycardia) occurring in a specified time interval is not affected by when preceding events occurred. For example, the probability of a patient having tachycardia within the next week is not influenced by whether his most recent attack was yesterday, last week, or last month. Second, the probability of a specified number of events Another important clinical implication of this study is that there seems little point in hospitalizing these patients "for observation" even if they require a physician's assistance for terminating an attack. That a patient had tachycardia today does not increase the likelihood that he will have it tomorrow. Patients can safely be discharged after short-term treatment in an emergency room, outpatient clinic, or physician's office.
The properties of a Poisson process are also useful for understanding how the tachycardia-free periods can be used "to measure" paroxysmal supraventricular tachycardia in a scientific study. As noted above, in a Poisson process the probability of an event occurring in a specified time interval is not affected by when the previous event occurred. This property follows from our having demonstrated that the tachycardia-free periVol. 70, No. 1, July 1984 ods followed an exponential probability distribution; however, we also tested this property by calculating the cumulative percentage of patients free of tachycardia during a 60 day follow-up period for the intervals dose-TI and TI-T2. The interval dose-TI was measured arbitrarily from the first dose of treatment; the time of the immediately preceding attack was not even noted and could have been the previous day or any time in the previous months. The interval TI-T2 was measured between two consecutive attacks. These cumulative curves dose-TI and TI-T2 were strikingly reproducible ( figure 3, A) .
We were concerned that some patients might have tachycardia before their medicine reached steady-state plasma drug levels. 12 To assess how pharmacokinetics affected our measure of efficacy, we defined another interval, steady-state-TI. We symptoms. 14 Our measurement method is thus consistent with our customary clinical practice. The method also treats all symptomatic tachycardia as qualitatively equal; any attack that persists long enough for the patient to transmit his electrocardiogram (a few minutes) is an equal "failure. " Obviously, clinical experience shows that some attacks are more severely symptomatic or last longer than others. Despite these reservations, the simplicity of measuring the tachycardia-free period and its reproducibility in short-term studies have encouraged us to continue using it to study patients with symptomatic arrhythmias.
The most surprising finding in our study was that tachycardia occurred uniformly throughout a dosing interval ( figure 4, A) ; we had expected to find that most attacks occurred late in a dosing interval when plasma drug levels were lowest. Peak plasma verapamil and diltiazem levels may be three times as high as their respective trough levels in these patients,"5 16 but peak levels did not appear to provide substantially more antiarrhythmic protection. This finding is consistent with our observation that the efficacy of orally administered verapamil was the same whether the drug was given every 8 hr or every 6 hr if the total daily dose was constant.'3 Taken together, these findings suggest that keeping trough plasma drug levels high by frequent drug administration is not important if the total daily dose delivered is constant. If this observation is confirmed for other drugs and other arrhythmias, it would greatly simplify antiarrhythmic drug administration.
We cannot be certain of the explanation for this phenomenon, although it may be that the concentrationresponse relationship at the drug doses we used was nearly flat.
We also were interested to observe that the occurrence of paroxysmal supraventricular tachycardia in our treated patients was related to time of day. No patient reported having tachycardia between midnight and 9 A.M. Since we cannot detect asymptomatic arrhythmias with our system, it is possible that patients simply were unaware of their arrhythmias while they were asleep. Alternatively, high vagal tone during sleep may have prevented tachycardia altogether.
Paroxysmal supraventricular tachycardia is commonly referred to as a "benign" arrhythmia because it is usually associated with low morbidity. Nevertheless, during the past 15 years this tachycardia has been studied extensively with the techniques of intracardiac recording and programmed stimulation because it is a naturally occurring "model" reentrant arrhythmia. '7 These same methods eventually were applied to the study and treatment of more serious arrhythmias such as ventricular tachycardia. We believe that paroxysmal supraventricular tachycardia can be exploited similarly as a model arrhythmia to study the spontaneous course of paroxysmal tachycardias and to study the pharmacologic variables responsible for their successful therapy.
